Objective: Bone grafts in patients with cleft lip and palate can undergo a significant amount of resorption. The aim of this study was to investigate the effects of bisphosphonates (BPs) on the success of bone grafts in rats.
necessitating additional expansion procedures and bone graft surgeries (Jia et al., 2006) . This repeated treatment has a number of adverse consequences, including surgical morbidity, lengthened overall orthodontic treatment duration and associated dental problems, decline in the patient's mental health, and increased financial burden (Hupp et al., 2008) . It is, therefore, imperative to develop improved and innovative therapeutic modalities to obtain reproducible outcomes and to augment the clinical success of cleft bone graft surgery in patients with CLP.
An imbalance of anabolic and catabolic activity during bone graft incorporation is a major cause of bone graft failure (Burchardt and Enneking, 1978) . Researchers have investigated different methods to increase the anabolic activity of osteoblasts as a way to achieve successful clinical outcomes. These methods include utilization of fibrin glue (Segura-Castillo et al., 2005) , platelet rich plasma (Marukawa et al., 2011) , and bone morphogenetic proteins . Although early results are promising (Ayoub et al., 2016) , the adverse effects of such methods, including hematoma formation and long-term growth effects, are alarming and have prevented their routine use (Smith et al., 2008; Alonso et al., 2010; Argintar et al., 2011) .
Incorporation of a bone graft involves not only formation but also resorption of bone in the grafted area. Decreasing the rate of graft resorption is particularly important for cleft bone grafting, as studies measuring bone loss of grafts using computed tomography (CT) scans report loss of bone volume as high as 64% after 1 year (Feichtinger et al., 2006) . Bone grafting in the intraoral cleft is prone to high resorption rates for several reasons: (1) tension developing from the mucoperiosteal flap and dehiscence (Kortebein et al., 1991; Rossell-Perry, 2015) , (2) bacterial infections specific to oral-nasal environments (Johanson et al., 1974 , Enemark et al., 1985 Lilja et al., 1987; Rossell-Perry, 2015) , and (3) the absence of mechanical stress, which is required for increased bone formation and decreased bone resorption as stated in Wolff's law (Bergland et al., 1986; Frost, 2004) . To date, there have been limited cleft bone graft studies to determine if new bone formation could be enhanced by limiting graft resorption, particularly with consideration of the intraoral environment. Limiting the increased resorption rate using antiresorptive agents is a promising new method that can significantly improve the clinical success of cleft bone graft surgery in treating patients with CLP.
Bisphosphonates (BPs) are promising antiresorptive drugs medically used to prevent bone loss by binding to hydroxyapatite in bone and leading to osteoclast dysfunction (Russell et al., 2008) . Previous studies have shown the protective role of BPs against bone allograft resorption by either soaking bone graft materials in BPs (Aspenberg and Astrand, 2002; Kesteris and Aspenberg, 2006) or administering a single injection subcutaneously (Tagil et al., 2006) . However, these methods have not yet been established for bone grafting in CLP models. A numbers of non-intraoral critical-sized defect (CSD) animal models have been used to study bone graft incorporation at the preclinical level; nonetheless, these models fail to accurately represent bone grafting in patients with CLP as intraoral factors such as the oral bacterial flora, mastication forces, and salivary components were not present (Springer et al., 2005; Aghaloo et al., 2010) .
In this study, we set our aims to (1) develop a novel animal model to accurately mimic a cleft bone graft in the oral cavity and (2) examine the role of BPs in preventing bone resorption following cleft bone grafting with an emphasis on different time points of single BP administration. Specifically, in order to determine an optimal window for BP delivery, BP systemic administration was given at the time of surgery and at 1 week and 3 weeks after surgery. We hypothesized that a delayed single dose of BP administration would improve bone volume as compared with controls and administration at the time of surgery.
MATERIALS AND METHODS

Animals
To first establish a novel intraoral CLP model, animals were divided into two groups: (1) control: defect without bone graft (n ¼ 3) and (2) graft: defect with graft (n ¼ 4). Isograft bone was harvested from the iliac crest and femur of a Fischer F344 Inbred donor rat. All animals were euthanized at 6 weeks postoperatively for micro-CT and histologic analysis.
Based on a feasibility study, a power analysis was
) 2 ) such that eight rats would be required in each group to achieve a power level of 0.8 and a ¼ 0.05. The animal research protocol for the main experiment was approved (ARC 2012-027-02A) by the UCLA Animal Research Committee. A total of 39 female 15-week-old Fischer F344 Inbred rats were purchased (Charles River Laboratories, Inc., Wilmington, MA) and housed in a light and temperature controlled environment. The rats were divided into five groups: (1) graft/ saline: bone graft with systemic saline injection (n ¼ 8);
(2) graft/BP/T0: systemic BP injection at the time of surgery (n ¼ 8); (3) graft/BP/T1: systemic zoledronic acid (ZA) injection 1 week postoperative (n ¼ 8); (4) graft/BP/T2: systemic ZA injection 3 weeks postoperative (n ¼ 8); (5) control: the defect was created but no bone graft was placed (n ¼ 3). Four F344 Inbred rats were used as bone isograft donors.
Surgical Procedure
Bone Graft Harvest
For donor animals, an incision was made on the lower back and the skin reflected. Soft tissue was separated through blunt dissection to gain access to the pelvic bone. The corticocancellous bone from the iliac crest and femur was harvested. A glass mortar and pestle were used to manually grind the corticocancellous bone into fine particles with sterile saline, which were then placed on ice for immediate use.
Creation of a Critical-Sized Bone Defect
Recipient animals were anesthetized with isoflurane (4% to 5%), followed by intraperitoneal injection of ketamine (40 mg/kg) and xylazine (10 mg/kg). Bland ophthalmic ointment was applied to prevent corneal desiccation. The first dose of analgesic, buprenorphine (0.01 to 0.05 mg/kg), was given immediately after the induction of anesthesia to allow it to take effect before the first incision was made. The animals received 0.3 mL of 1% lidocaine with 1:5000 epinephrine submucosally along the alveolar ridge. A 1-cm longitudinal mucosal incision was made along the junction between the hard palate and alveolus. The dentoalveolar periosteum was elevated to expose alveolar bone distal to the maxillary incisors. Using a hand-operated, low-speed power drill, a circular 3-mm midpalatal defect was created distal to the upper incisors using a 3-mm diameter trephine bur, generating an accurate and consistent defect size for each surgery. Due to the length of the maxillary incisors, the defect was placed in the midpalate to avoid dental root damage ( Fig. 1 ). After adequate hemostasis using pressure and gauze, the harvested isograft was placed into the defect and the mucosa reapproximated. Postoperatively, each animal received subcutaneous injections of buprenex (0.05 mg/kg) two times a day for 2 days as analgesia. Trimethorprimsulfa was placed in the drinking water (5 mL trimethorprimsulfa per 500 mL water) for a period of 2 weeks postsurgery, beginning the day before surgery, to prevent infection.
Placement of the Bone Graft
Harvested cancellous bone was placed in a 30-lL syringe with the tip removed. The bone was packed into the syringe and saline blotted for dense concentration of bone without desiccating the graft material. Then, 7 lL was dispensed into each animal defect for consistency of volume and concentration. 
BP Delivery
A single 0.1 mg/kg subcutaneous injection of ZA was administered to the animals at 1 week postsurgery for the pilot study. For the graft/BP groups, ZA was administered at various time points: at the time of surgery (T0), 1 week postsurgery (T1), or 3 weeks postsurgery (T2). For the graft/saline group, a single systemic injection of saline was administered 1 week postsurgery. Six weeks postsurgery, all animals were euthanized and the maxilla harvested.
Data Analysis
Micro-CT Analysis
The maxilla was dissected and fixed with 4% (weight/ volume) paraformaldehyde in 0.1 M phosphate-buffered saline solution for 24 hours. The samples were scanned using a high-resolution micro-CT (SkyScan 1172, Sky-Scan N.V., Kontich, Belgium), at an image resolution of 9.87 lm, with 70 kV and 141 lA x-ray source and 0.5 mm aluminum filter. Then three-dimensional (3D) image datasets were reconstructed from two-dimensional x-ray images using NRecon Reconstruction 64-bit software (SkyScan N.V), which processes appropriate image correction steps including ring artifact correction, beam hardening correction and fine-tuning. After acquisition of the datasets, the images of samples were viewed and reoriented on each 3D plane with Data-Viewer 63-bit version software (SkyScan N.V.) to align the palatal defects parallel to the transaxial plane to minimize analysis errors.
A 3D volumetric analysis was performed using CTAn software v1.16 (SkyScan N.V.). To ensure consistency of results, all analyses were repeated at a separate time point by a single rater. The region of interest was outlined with a 3-mm circle on consecutive transaxial sections in order to create a uniform, cylindrical-shaped volume of interest, which encloses the entire defect area. Grey threshold values were determined by approximating images to their true morphology. Bone volume (BV) and tissue volume (TV) were measured to calculate percent bone volume (BV/TV) of each graft site, and bone mineral density (BMD) was also calculated.
Histologic Analysis
After micro-CT analysis, the samples were decalcified for 20 days in 10% ethylenediaminetetraacetic acid (EDTA) (0.1 M, pH¼7.1) solution. During decalcification, the solution was changed every 2 days. After decalcification, the samples were dehydrated through graded ethanol and embedded in paraffin. Then, the samples were sectioned coronally in 10-lm sections.
Sections were stained with hematoxylin and eosin (H&E) by the UCLA Tissue Procurement Core Lab to visualize bone graft morphology. Mineralized area/total area of mineralized sections was calculated using Advanced SPOT 4.6 software (SPOT Imaging Solutions, Sterling Heights, MI) at 43 magnification.
Evaluating Osteoclasts
One section from each animal was stained for tartrate-resistant acid phosphatase (TRAP), using a TRAP staining kit (Sigma Aldrich, St. Louis, MO). The slides were de-paraffinized at 608C for 30 minutes, then rehydrated with xylene and graded ethanol solutions. The slides were then incubated in acetate buffer (pH 5.0) containing naphthol AS-MX phosphate, Fast Red Violet LB Salt, and 50 mM sodium tartrate. They were placed in humidity chambers with no light exposure at 378C for 2 hours. Slides were then counterstained with hematoxylin for 8 seconds to differentiate between soft and hard tissues and then rinsed with tap water. Samples were mounted with aqueous mounting solution. Osteoclasts were defined as multinucleated TRAPþ cells. For quantification, the number of TRAPþ multinuclear cells (3 nuclei) on the external surfaces of the bone was counted using the surgical defect as the field of view. The number was presented as number of TRAPþ cells/mm 2 bone area. Quantification was performed with a single operator blinded to the clinical information at two separate time points using Advanced SPOT 4.6 software (SPOT Imaging Solutions).
Statistical Analysis
The data were expressed as means and standard deviations for each group. Means were compared using parametric analysis of variance (ANOVA). Examination of residual error normal quantile plots and the Shapiro-Wilks test for normality confirmed that the data followed the normal distribution, allowing AN-OVA to be used among the groups: (1) graft/saline, (2) graft/BP/T0, (3) graft/BP/T1, and (4) graft/BP/T2 (a ¼ 0.05). Mean differences among subgroups under the ANOVA model were evaluated using the Fisher least significant difference criterion. Computations were carried out using JMP 12.0 (SAS Inc., Cary, NC). Adjusted values of P , .05 were considered statistically significant.
RESULTS
Establishment of Intraoral Cleft Bone Graft Model in Rats
To develop an animal model for cleft bone graft that can better represent the intraoral environment, we created a circular, midpalatal CSD in rats. A defect 3 mm in diameter was created in the palatal areas reproducibly without any technical difficulties (Fig. 1 ). In addition, oral mucosal tissues at the surgical lesions closed within 1 week and healed without any complications, including breathing problems, nasal obstruction, bleeding, and infection. Using this model, we first examined the bone-healing patterns of the CSD with or without bone graft. Micro-CT analysis of the control group confirmed that this newly developed intraoral defect was indeed nonhealing (Fig. 2a, top) . Conversely, when bone graft was placed, significant incorporation of bone occurred (Fig. 2a, bottom) . This difference in healing pattern was confirmed up to 10 weeks. Further quantification of mineralized tissues in the defect area showed a significant increase in bone volume fraction (BV/TV) in the graft group compared with the control group (Fig. 2b) . These results indicate the successful establishment of an intraoral cleft bone graft model in rats.
Effects of BPs at the Different Delivery Time Points in the Cleft Bone Graft Rat Model
BPs are known to reduce bone resorption leading to increased bone volume. (Russell et al., 2008) As such, we next examined the effects of administering BPs at different time points during the course of palatal bone graft healing: systemic BP injection at the time of surgery (graft/BP/T0), 1 week after surgery (graft/BP/ T1), and 3 weeks after surgery (graft/BP/T2). Systemic injection of saline at the time of surgery was used as a control group (graft/saline). As an additional control, the defect was created without bone graft placement (control). The group assignment and experimental timeline are outlined in Figure 3 . Oral mucosal tissues at the surgical lesions in all groups, including BP injection groups, were completely healed and closed without any complications up to 6 weeks postsurgery.
Micro-CT 3D reconstructed images of the defect area reconfirmed the nonhealing defect in the control group and revealed integration of defect margins with existing palatal bone in the graft/BP/T1 and the graft/BP/T2 groups, indicating clinical success of the bone graft procedure (Fig. 4a ). Most of the graft/BP/T0 and graft/ saline animals had no union at the margins. Micro-CT analysis showed a significant increase in BV/TV in the graft/BP/T1 (45.4% 6 8.8%) and the graft/BP/T2 (46.1% 6 12.4%) group compared with the graft/saline group (31.0% 6 7.9%) (Fig. 4b ). There was no statistically significant difference in BV/TV between the graft/BP/T1 and graft/BP/T2 groups. Interestingly, BP administration at the time of surgery did not increase bone volume and in fact had the lowest BV/ TV (27.6% 6 5.9%) (Fig. 4b) . Our BMD analysis, however, did not show significant difference among groups (Fig. 4c) .
Similarly, H&E staining of the defect verified a clear increase in bone mass in the graft/BP/T1 and the graft/ BP/T2 groups (Fig. 5 ). There was a significantly increased mineralized area/total area in the graft/BP/ T1 (0.72 6 0.10) and the graft/BP/T2 (0.68 6 0.09) groups compared with the graft/BP/T0 group (0.21 6 0.08) and the graft/saline group (0.24 6 0.06) (Fig. 5b ). In these delayed BP groups, more exuberant angiogenesis and new bone formation were evident with FIGURE 2 Bone grafting in palatal defect. a: 3D micro-CT images of the control group showed that the newly developed intraoral defect was nonhealing after 10 weeks, while the graft group demonstrated a successful bone grafting at 6 weeks postoperatively. b: Quantification of bone volume by micro-CT analysis showed a statistically significant increase in bone volume in the graft group (P , .05). A Student's t test was used to calculate differences. Error bars show standard error.
prominent vasculature and a greater number of osteocytes in mineralized tissues. In addition, evident amplification of osteoblasts and integration of new bone with bone graft were visualized. In the graft/BP/ T1 and the graft/BP/T2 samples, complete fusion of defect margins with existing palatal bone was present histologically confirming 3D micro-CT images, while most of the graft/saline and graft/BP/T0 groups had no union (Fig. 5a ). Indeed, one of the rats in the graft/ saline group showed severe bone resorption and lacked new bone formation entirely, indicating the clinical unpredictability of oral cleft bone graft surgery (Fig.  5) . Interestingly, all animals in the graft/BP/T0 group showed significantly decreased bone volume with signs of acute inflammation (Fig. 5a ). Graft/BP/T0 H&E images demonstrated extensive infiltration of inflammatory cells in the entire defect and high resorption of bone graft along with lack of new bone formation (Fig.  5a ).
TRAP staining showed no significant difference in quantity of osteoclasts, with 25% detached from the bone surface; however, 3.75% of TRAPþ multinucleated osteoclasts in BP-treated rats exhibited abnormal morphology, appearing rounded and detached from the bone surface (Fig. 6) . Taken together, our data suggest that delayed BP administration following the cleft bone graft surgical procedure enhanced the formation of bone at the grafted sites.
DISCUSSION
In this study, we showed successful establishment of an intraoral CSD rat model that best represents the bone grafting in patients with CLP. Also, we demonstrated the use of BPs to suppress bone resorption without any adverse effects in this rat model, providing preclinical evidence that a single dose of BP can be utilized to improve cleft bone graft in patients.
Currently, there are several animal models for CLP but with multiple shortcomings. While genetic rat models for CLP exist, they die soon after birth, preventing the study of CLP postnatally (Juriloff and Harris, 2008) . Therefore, in order to study bone grafting in oral clefts, a CSD needs to be created to mimic the cleft. A common CSD model used to study bone graft incorporation involves a circular defect creation in the calvaria as this design provides good surgical access and high reproducibility (Aghaloo et al., 2010) . However it fails to accurately represent bone graft in patients with CLP as intraoral factors such as the oral bacterial flora, mastication forces, and salivary components are not present in these models. We recreated a previously published intraoral CSD design in which the rats experienced severe incisal root damage. The defect cut through the tooth, causing unnecessary pain and introducing pulpal bleeding and cells into the defect ). In addition, the design had an irregular shape, compromising reproducibility of the study. Here, we developed a novel animal model that accurately simulates clinical conditions by creating a palatal defect 3 mm in diameter that circumvents problems with lethal genetic models. Therefore, our model represents more accurately the conditions associated with CLP grafting, such as oral bacterial flora, mastication forces, and salivary components. Furthermore, we demonstrated that our novel palatal defect was nonbone healing and resulted in complete closure of the overlaying soft tissues in 6 weeks with no significant complications. All rats used in this study survived without postoperative complications, demonstrating the surgical predictability and reproducibility of this procedure.
The gold standard for graft sources in patients with CLP is autologous bone (Lichte et al., 2011) with the iliac crest (Boyne and Sands, 1972) , calvaria (Wolfe and Berkowitz, 1983) , or tibia (Kalaaji et al., 2001) being the most common sources. This is because autografts are osteoinductive, osteoconductive, and nonimmunogenic (Dimitriou et al., 2011) . In this study, instead of using autologous bone, we used Fischer F344 Inbred rats as donors for bone graft material not only to minimize any complications originating from surgery for obtaining autologous bone but also due to their genetic continuity, resulting in isografts that closely mimic autografts. Indeed, our histologic findings showed minimal inflammatory reaction against isograft materials, demonstrating successful establishment of an effective intraoral CSD-based animal model that can be applied to the study of different agents in future studies.
A previous study showed that delaying BP administration may allow the endogenous anabolic and catabolic responses to establish themselves before administering the drug, resulting in a higher rate of bone turnover (Little et al., 2005) . In a femoral osteotomy model, BP injections delayed by 2 weeks had increased callus volume and density Mathavan et al., 2013) . Indeed, upon examining the effect of timing of BP delivery on bone FIGURE 4 Micro-CT images and analysis. Bone volume (BV) and tissue volume (TV) was measured to calculate percent bone volume (BV/TV) of each graft site. a: 3D micro-CT images of the five groups demonstrated a clear increase in bone volume and bone integration in the graft/BP/T1 and graft/BP/ T2 groups. b: Quantification of bone volume by micro-CT analysis showed statistically significant increase in bone volume in graft/BP/T1 and graft/BP/ T2 groups. The graft/BP/T0 group had similar percent bone volume to the graft/saline group. ANOVA with post hoc t tests was used to calculate differences. * Statistically significant, P , .05. Error bars show standard error. c: Quantification of bone mineral density by micro-CT analysis did not show a statistically significant difference between groups.
graft success, we observed a significant increase in BV/TV following delayed BP administration at 1 and 3 weeks postoperatively. Furthermore, these results were confirmed through histologic analysis, which found a significant increase in mineralization following delayed BP administration. These results suggest that when BPs are adminis-tered at the time of surgery, osteoclast inhibition results in an inability to resorb the dead bone that now occupies the space. Consequently, proper bone remodeling is also inhibited. Moreover, the results suggest that BPs, which have greater affinity for bone undergoing active remodeling, bind at a greater rate to the grafted region after first FIGURE 5 H&E staining images. a: H&E stained coronal sections taken at 43 and 103 magnification confirmed increased bone volume in the graft/ BP/T1 and graft/BP/T2 groups, with evident amplification of osteocytes, integration of new bone with bone graft, and complete fusion of defect margins with existing palatal bone. The graft/BP/T0 group showed significantly decreased bone volume with signs of acute inflammation. b: Quantification of the ratio of mineralized area to total area for each group using Advanced SPOT 4.6 software (SPOT Imaging Solutions) showed significantly increased mineralization in the graft/BP/T1 and graft/BP/T2 groups.
allowing time for the anabolic and catabolic responses to establish themselves, thereby resulting in an increased anticatabolic response (Little et al., 2005) .
Additionally, the bone remodeling rate in the maxillary bone, which is more relevant for CLP studies, is higher than bone remodeling in other anatomic regions (Huja and Beck, 2008) . In a study of young dogs, a threefold to sixfold difference in bone turnover rate between the maxilla and femur was observed (Huja et al., 2006; Huja and Beck, 2008) . Accordingly, this high bone remodeling rate in the maxilla may allow for even greater binding of BP (Bertoldo et al., 2007) , thereby inducing a higher anticatabolic effect in cleft bone grafting and shifting the balance between osteoclastic and osteoblastic activity toward increased bone formation (Wermelin et al., 2007; Aspenberg, 2009) .
Interestingly, BP administration at the time of the surgery resulted in a lowest BV/TV (Fig. 4) . Studies have found that BP accumulation in bone can be directly toxic to the oral epithelium and can impair epithelial homeostasis and repair by inhibiting re-epithelialization, thereby delaying soft tissue healing and increasing the likelihood of secondary infections (Reid et al., 2007; Donetti et al., 2014) . However, there was complete primary soft tissue healing by 1 week after the bone graft surgery, suggesting that soft tissue toxicity of BP is less likely to be the reason for this differences in BV/TV.
On the other hand, BP is known to induce inflammation as clinically evident by occurrence of acute phase responses in 30% to 40% of intravenous BP users (Adami et al., 1987) . Indeed, animals in the graft/BP/T0 group exhibited signs of extensive acute inflammation upon histologic examination in addition to the lower BV/TV (Fig. 4) . BP can induce expression of proinflammatory cytokines, such as interleukin-6 and tumor necrosis factor-a, both in vitro and in vivo (Schweitzer et al., 1995; Thiebaud et al., 1997) . As such, it is possible that administration of BP immedi-ately after the surgery exacerbates and prolongs proinflammatory signals in the grafted areas, preventing proper healing process and resulting in lower BV/TV. BP prevents bone resorption by targeting osteoclasts and suppressing their functions (Russell et al., 2008) . When we examined the presence of osteoclasts using TRAP staining, we observed no significant difference in the number of matured TRAPþ osteoclasts between different treatment groups. However, it is noteworthy that 3.75% of TRAPþ multinucleated osteoclasts in BP-treated rats exhibited abnormal morphology, appearing rounded and detached from the bone surface (Fig. 5) . In a study utilizing transgenic mice that overexpressed TRAP, no significant difference in osteoclast number was observed despite a significant decrease in trabecular bone (Angel et al., 2000) , suggesting that TRAP expression is not directly associated with osteoclast number. Other studies examining highdosage BP treatment in animals also found no difference in TRAPþ cells (Kang et al., 2013; Park et al., 2013; Williams et al., 2014) , but found that they had abnormal morphology in BP-treated groups (Kang et al., 2013) . This morphologic aberration may indicate a disruption of osteoclast function. Alternatively, another explanation of our results may be that at the time of euthanasia (6 weeks), most of the dysfunctional osteoclasts affected by BP had already undergone apoptosis, while the newly generated osteoclasts showed normal resorptive activity. Studies have shown that the osteoclast life span ranges from just a few days (Miller and Bowman, 2007) to 6 weeks (Marks and Seifert, 1985) . Future studies in which animals are euthanized soon after BP administration with multiple shorter intervals of sacrifice could demonstrate osteoclast activity levels as a function of time.
Although we provide compelling evidence that proves antiresorptive effects of BP in cleft bone graft at the preclinical level, pleotropic effects of BP should be carefully considered before translating our findings onto the clinical level. First, BP is known to inhibit or delay permanent tooth eruption, as demonstrated by other studies showing that daily injections of BP at high concentrations for up to 1 month resulted in delayed tooth eruption or no eruption in animals (Grier and Wise, 1998; Bradaschia-Correa et al., 2007) . However, close examination revealed that these previous studies administered much higher BP dosages, ranging from 1.25 to 2.5 mg/kg daily injections, compared with the 0.1 mg/kg single injection used in our study based on the commonly used therapeutic low dose given to humans for treatment of osteoporosis and osteogenesis imperfect (OI) (Schmitz and Hollinger, 1986; Ward et al., 2007) . Second, there are concerns regarding the long-term effects on bone remodeling and maturation when BP is used in growing patients. However, it should be noted that BP therapy for OI in children has become a safe and established protocol to increase BMD and reduce fracture incidence (Glorieux et al., 1998; Seikaly et al., 2005; DiMeglio and Peacock, 2006) . The literature conclusively shows that BP use in growing patients is justified, but it should be used carefully in regard to transient but possibly reversible changes at bony growth plates. Third, long-term use of BP is associated with the risk of developing BP-related osteonecrosis of the jaw (BRONJ), particularly with intravenous administration (Aghaloo et al., 2015) . The incidence of BRONJ ranges from 0.8% to 12% when used intravenously to treat hypercalcemia and bone metastases (Ruggiero et al., 2009) . However, a large study examining 64 children treated with BP for OI found 0% incidence of BRONJ (Malmgren et al., 2008) . In line with this finding, cleft bone grafting is done in the maxilla, where BRONJ is half as likely to occur compared with the mandible (Weeda, 2009 ). Based on these previous clinical studies, we anticipate the concentration of BP used in our palatal defect animal model poses a minimal risk for developing BRONJ.
In this study, the effect of systemic BP on cleft bone grafting was examined in female rats. Although a previous study reported that drug uptake by the bone between male and female rats presents similarly (Lin et al., 1992) , this current study can be further expanded by examining BP effects on males. In addition, further histologic analysis using calcein binding will be beneficial as this allows direct quantification of extracellular matrix mineral content in monolayer cultures of bone-forming cells such as primary osteoblasts (Hale et al., 2000) to further evaluate the effect of BPs on cleft grafting.
With the development of a novel palatal defect animal model, which can be applied to the study of different agents in regulation of endogenous metabolic activities during bone graft incorporation, we demonstrated that a single, delayed systemic injection of ZA significantly increased percent bone volume 6 weeks after bone graft surgery. This innovative approach resulted in the clinical success of bone grafts, with clear evidence of angiogenesis, osteocytes, and bony integration. In addition to establishing an effective model for studying the effects of various agents on bone grafting, this study demonstrates that the anticatabolic properties of BP could offer promising new clinical applications towards effectively managing patients with CLP.
